NPM1 and myelodysplastic syndrome: A third mutation in FLT3-ITD (fml-like tyrosine kinase 3) after NPM1 completes the path towards leukemogenesis, and patients with this combination of mutations, observed in 40% of those who have sAML derived from MDS, have a much poorer prognosis and shorter overall survival rate [2,60,96].